Did the FDA Remove the Heart Warning on Testosterone?

On February 28, 2025, the FDA ordered a class-wide labeling change for every testosterone product sold in the U.S.

The headline: the long-standing "boxed warning" tying testosterone to heart attack and stroke risk is being removed. But the same order added a new warning about blood pressure.

Here's what actually changed, what it doesn't change, and what it means if you're considering testosterone replacement therapy (TRT) in the Twin Cities.

Key Takeaways (TL;DR)

• The FDA removed the cardiovascular boxed warning from all testosterone products on February 28, 2025.

• The reason: the TRAVERSE trial of 5,246 higher-risk men found testosterone did not raise the rate of major cardiac events versus placebo.

• A new warning was added: testosterone can raise blood pressure, confirmed across the drug class in post-market studies.

• TRT is still prescription-only and approved only for men with low testosterone tied to a medical condition — not for normal age-related decline alone.

• Bottom line: the change reflects better evidence, not a green light to skip medical supervision. Monitoring still matters.

What exactly did the FDA change about testosterone labeling?

The FDA removed the cardiovascular boxed warning and added a blood pressure warning across all testosterone products.

On February 28, 2025, the FDA informed manufacturers of class-wide labeling changes for all testosterone products. Three things happened: the agency removed the Boxed Warning language about increased risk of adverse cardiovascular outcomes, added the results of the TRAVERSE trial to every product's label, and required a new warning that testosterone can increase blood pressure. A "Boxed Warning" is the FDA's strongest safety alert, so removing one is a significant signal about the strength of the underlying evidence. (Source: FDA)

Why was the heart-risk warning there in the first place?

It dated back to 2014, when early reports linked testosterone to heart attacks and strokes.

In January 2014, the FDA issued a safety communication about reported risks of stroke, heart attack, and death in men taking testosterone. Later that year the agency convened an advisory committee and called for an industry-wide clinical trial to settle the question. The warnings men have seen on testosterone labels for the last decade trace directly back to that period. (Source: FDA)

What is the TRAVERSE trial, and why did it change the FDA's mind?

TRAVERSE was the large trial the FDA required in 2014, and its results showed no increase in major cardiac events.

TRAVERSE followed 5,246 men aged 45 to 80 who already had cardiovascular disease or were at high risk for it — exactly the population most likely to be harmed if testosterone were dangerous to the heart. Published in the New England Journal of Medicine in 2023, it found that the rate of major adverse cardiac events in men taking testosterone was non-inferior to (statistically no worse than) those taking a placebo. That result is what led the FDA to drop the boxed warning. (Source: New England Journal of Medicine)

Does this mean testosterone therapy is now considered safe?

Safer on the heart-attack question, but not risk-free — and the new blood pressure warning is real.

Removing the boxed warning addresses one specific concern: major cardiac events like heart attack and stroke. It does not erase every risk. The same FDA order added a warning that testosterone raises blood pressure, a finding confirmed across the entire drug class in required post-market monitoring studies. Elevated blood pressure carries its own long-term cardiovascular consequences, which is why ongoing monitoring stays part of responsible treatment. (Source: FDA)

Who is testosterone therapy actually approved for?

Men with low testosterone caused by a diagnosed medical condition — not aging by itself.

The FDA approves testosterone only for men who lack or have low testosterone levels in connection with an associated medical condition. The label keeps a "Limitation of Use" stating it has not been established as safe or effective for low testosterone due to aging alone. In practice, that means a proper diagnosis — symptoms plus confirmed low blood levels — comes before any prescription. (Source: FDA)

What should I do with this information before starting TRT?

Get evaluated properly, and expect monitoring rather than a one-time prescription.

The label change is good news if you've been hesitant because of old heart-risk headlines, but it doesn't replace a workup. A responsible TRT program starts with bloodwork to confirm low testosterone, a review of your cardiovascular and blood pressure history, and a plan to recheck both your levels and your blood pressure on a schedule. If a provider offers testosterone with no labs and no follow-up, that's a red flag regardless of what the label now says.

---

Frequently Asked Questions

Q: Did the FDA remove the testosterone heart warning in 2025?

Yes. On February 28, 2025, the FDA removed the cardiovascular boxed warning from all testosterone products, based on the TRAVERSE trial. It simultaneously added a new warning about increased blood pressure.

Q: Is testosterone replacement therapy safe for the heart now?

The strongest evidence to date (the TRAVERSE trial) found no increase in major cardiac events versus placebo, which is why the boxed warning was removed. Testosterone can still raise blood pressure, so heart health monitoring remains part of treatment.

Q: Do I still need a prescription and bloodwork for TRT?

Yes. Testosterone is prescription-only and FDA-approved only for men with low testosterone tied to a medical condition. A legitimate program confirms low levels with bloodwork before treating and monitors you over time.

Q: Where can I get testosterone therapy near Edina, MN?

Men in Edina and the greater Minneapolis–Twin Cities area can be evaluated for TRT at [Practice Name]. We start with comprehensive lab testing, review your full health history, and monitor your testosterone and blood pressure throughout treatment. [Contact us / book a consultation] to find out whether you're a candidate.

Q: How do I know if I have low testosterone?

Common symptoms include low energy, reduced libido, difficulty building muscle, and mood changes but symptoms alone aren't enough. Diagnosis requires a blood test confirming low testosterone levels, which is why an in-person evaluation matters.

This article is for general education and reflects FDA labeling guidance as of February 28, 2025. It is not medical advice. Talk with a qualified provider about your individual situation before starting or stopping any therapy.

Sources

• U.S. Food and Drug Administration — FDA issues class-wide labeling changes for testosterone products (February 28, 2025)

• New England Journal of Medicine — Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) (2023)